

Addendum to the Notice of Annual General Meeting

The following addendum to the notice of Annual General Meeting, published on October 07, 2024 is being issued.

Clause 5 of the notice is hereby changed as follows:

The approval of related parties' transactions is moved under Special Business after clause 6. A statement of material facts in this respect is enclosed.

Statement of Material Facts Under Section 134(3) of the Companies Act, 2017

The related party transactions are primarily with the subsidiary companies. These transactions are approved by the Board of Directors, after recommendation of the Audit Committee pursuant to clause 15 of Listed Companies (Code of Corporate Governance) Regulations, 2019.

These transactions are being placed for the approval by shareholders in the Annual General Meeting. Details of the transactions as mentioned in note no. 41 of the unconsolidated financial statements is as follows:

Name of parties	Relationship	Transactions	2024	2023
			-----Rs.-----	
BF Biosciences Limited	80% owned subsidiary company	Sale of medicines	696,974,490	437,877,760
		Payment received against sale of medicine	696,974,490	437,877,760
		Short term borrowing extended to BFBL	-	170,000,000
		Short term borrowing repaid by BFBL	-	170,000,000
		Outstanding amount of short term borrowing	-	-
		Expenses incurred by BFBL on behalf of the Company - net	108,179,756	46,150,073
		Payments made to BFBL - net	107,106,594	44,761,586
		Receipts received by BFBL on behalf of the Company - net	1,073,162	1,388,487
		Purchase of medicines	825,204	23,594,211
		Payment made against purchase of medicine	825,204	23,594,211
		Corporate guarantee income	7,020,000	7,020,000
		Payment received against corporate guarantee income	7,020,000	7,020,000
		Markup income	-	950,806
		Payment received against markup income	-	950,806
Farmacia	98% owned subsidiary partnership firm	Sale of medicines - <i>net of returns and discounts</i>	242,699,653	122,401,534
		Payment received against sale of medicine	242,699,653	122,401,534
		Rentals	6,524,784	5,931,624
		Share of profit reinvested	8,751,051	23,973,654
Employees provident fund	Post employment benefit fund	Contribution towards employees' provident fund	73,051,362	64,105,911
Key Management Personnel	Key management personnel	Remuneration including benefits and perquisites	55,738,708	49,020,971
		Advance given against salary	-	793,333
		Cash Dividend	-	8,400
		Issuance of bonus shares as dividend	-	3,360
KFW Factors (Private) Limited	Common directorship	Cash Dividend	-	49,721,645
		Issuance of bonus shares as dividend	-	19,888,658
Osman Khalid Waheed	Chief Executive Officer	Remuneration including benefits and perquisites	50,628,052	40,953,794
		Cash Dividend	-	12,947,025
		Issuance of bonus shares as dividend	-	5,178,810
		Meeting Fee	50,000	70,000
Directors other than CEO	Non-Executive Directors	Rental expense paid for building in use	5,749,518	6,544,527
		Cash Dividend	-	4,670,330
		Issuance of bonus shares as dividend	-	1,868,132
		Meeting Fee	390,000	560,000
Khan and Piracha	Common directorship	Payment made against services received	-	455,000
National Management Foundation (LUMS)	Common directorship	Donations	5,000,000	2,312,752
		Event sponsorship	7,500,000	-
		Payments against trainings	2,262,000	-